Frazier Sees Opportunity For New $987m Fund Despite Financial Market Turmoil

Start-Ups, Growth-Stage And Public Investments All Targeted

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Frazier Life Sciences managing partner James Topper described how the firm will use its 11th fund to launch new companies, support growing firms and take advantage of public market opportunities.

Entrepreneur using digital technology for business start-up
30%-40% of Frazier's fund will back start-ups; 20% is reserved for public companies • Source: Alamy

Some things have changed since January 2020, when Frazier Life Sciences closed its 10th venture capital fund, totaling $617m, but much remains the same now that the firm has raised its 11th fund, totaling $987m. Despite the macroeconomic and global political issues causing havoc in the public financing market, scientific innovations continue to generate ideas for new start-ups that many investors are eager to finance in anticipation that big pharma companies eventually will buy them.

Also, the COVID-19 pandemic that started in 2020 – which drew investors into the biopharmaceutical industry that were not heavily...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

spo

Akash test for clone

Test article to check the clone issue

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.